Measles
Also known as: Rubeola
Methodology & AI Transparency ⓘ
Measles Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Measles is an infectious disease caused by a virus.
- 2 Real-world patient consensus: Diagnostic registry B05.9: Measles is managed within Skin & Dermatology (aka Rubeola).
- 3 Typical cash cost range: Primary evaluation for Measles incorporates dermoscopy or punch in Measles (B05.9: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Measles: 25-Hydroxy Vitamin D in Measles (B05.9: & hs-CRP) (25(OH)D 40–65 ng/mL (B05.9)) and Affected Body Surface in Measles (B05.9: Area (BSA /).
Ask our AI Specialists anything about Measles
What Is Measles?
Measles is an infectious disease caused by a virus. It spreads easily from person to person. It causes a blotchy red rash. The rash often starts on the head and moves down the body. Other symptoms include: Fever Cough Runny nose Conjunctivitis (pink eye) Feeling achy and run down Tiny white spots inside the mouth Sometimes measles can lead to serious problems. There is no treatment for measles, but the measles-mumps-rubella (MMR) vaccine can prevent it. "German measles", also known as rubella , is a completely different illness. Centers for Disease Control and Prevention
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Measles (B05.9) involves cutaneous immune skewing in Measles (B05.9: (Th2/IL-4/IL-13 in atopic). Cross-referenced with NIH MeSH (Measles), progression correlates with shifts in 25-Hydroxy Vitamin D in Measles (B05.9: & hs-CRP) (25(OH)D 40–65 ng/mL (B05.9)).
Common Symptoms & Clinical Signs
- • Conjunctivitis (pink eye)
- • Feeling achy and run down
- • Presentation of Measles (B05.9): compromised epidermal barrier in Measles (B05.9: with dryness, fissuring,)
- • Secondary Measles clinical sign: post-inflammatory hyperpigmentation, facial in Measles (B05.9: flushing, or pitted)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Measles Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B05.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Measles (B05.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (B05.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Measles (B05.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (B05.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Measles (B05.9: ALT (if systemic) | Within baseline reference limits (B05.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Measles
Treatment selection for Measles depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Measles)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Correlation of protection against varicella in a randomized Phase III: What a 5,803-Participant Study Found Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. Vaccine • 2021-06-08 • Phase III Randomized Trial | N = 5,803 | 90/100 | PMID 33736915 ↗ |
| Can This Approach Help? Inside the Latest Research on Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc Maintenance of response using reduced-dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38752592 ↗ |
| New Insights on Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with: What a 360-Participant Study Found Results indicated that there is non-interference of MMR vaccine with Vi-DT and Vi-DT conjugate vaccine could be considered as an addition to the EPI schedule among children at risk of contracting typhoid. Vaccine • 2022-09-22 • Phase III Randomized Trial | N = 360 | 87/100 | PMID 36064672 ↗ |
| New Insights on Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals: What a 888-Participant Study Found It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years... Vaccine • 2023-10-20 • Phase III Randomized Trial | N = 888 | 87/100 | PMID 37659893 ↗ |
| New Insights on Clinically- versus serologically-identified varicella: A hidden infection burden.: What a 744-Participant Study Found About one-third of children not vaccinated against varicella and not diagnosed with varicella developed an anti-VZV immune response, suggesting subclinical varicella occurrence. Human vaccines & immunotherapeutics • 2021-10-03 • Phase III Randomized Trial | N = 744 | 87/100 | PMID 34181506 ↗ |
Measles Patient Community & “People Like Me” Threads
Filter Measles community threads and patient logs by age, biological sex, dosage, and treatment duration.